Kugelberg Welander Spinal Muscular Atrophy Follow-up
- Author: Joyce L Oleszek, MD; Chief Editor: Stephen Kishner, MD, MHA more...
Further Outpatient Care
See the list below:
- Patients with spinal muscular atrophy (SMA) should have frequent follow-up care for symptomatic control of their disease. Respiratory function, nutritional state, orthopedic status, and equipment needs should be assessed at each visit. Pain control, preventative medicine, surgical intervention, and physical therapy are all essential parts of the patient's long-term care. The multidisciplinary approach, which includes family members, social workers, therapists, and physicians, is important to assist the patient in maintaining a high quality of life.
See the list below:
- Plantar flexion contractures
See the list below:
- Patients with spinal muscular atrophy experience a progressive loss of motor function that usually affects the legs before it does the arms, and the proximal muscles before the distal ones.
- Patients who have never climbed stairs without a rail lose walking ability by their midteens. Patients who develop normal walking skills prior to the onset of muscle weakness can maintain this ability until the third or fourth decade.
- Life expectancy for individuals with SMA type III has been shown to be similar to that of the general population.
- See Mortality/Morbidity.
Bradley WG, ed. Neurology in Clinical Practice. 5th ed. Philadelphia, Pa: Butterworth-Heinemann/Elsevier; 2008.
Herring JA, ed. Tachdjian's Pediatric Orthopaedics. 4th ed. Philadelphia, Pa: Saunders/Elsevier; 2008.
Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007 Aug. 22(8):1027-49. [Medline].
Russman BS, Buncher CR, White M, et al. Function changes in spinal muscular atrophy II and III. The DCN/SMA Group. Neurology. 1996 Oct. 47(4):973-6. [Medline].
Zerres K, Rudnik-Schöneborn S, Forrest E, et al. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997 Feb 27. 146(1):67-72. [Medline].
Lin LC, Jong YJ. Pulmonary function assessment in patients with spinal muscular atrophy type II and type III. Acta Paediatr Taiwan. 2004 Jan-Feb. 45(1):15-8. [Medline].
Muscular Dystrophy Campaign sponsored workshop: recommendation for respiratory care of children with SMA type II and III. Neuromuscular Disord. 2003. 13:184-189.
Simic G. Pathogenesis of proximal autosomal recessive spinal muscular atrophy. Acta Neuropathol. 2008 Jul 16. [Medline].
Mattis VB, Bowerman M, Kothary R, et al. A SMNDelta7 read-through product confers functionality to the SMNDelta7 protein. Neurosci Lett. 2008 Jun 26. [Medline].
Sedghi M, Behnam M, Fazel E, et al. Genotype-phenotype correlation of survival motor neuron and neuronal apoptosis inhibitory protein genes in spinal muscular atrophy patients from Iran. Adv Biomed Res. 2014. 3:74. [Medline]. [Full Text].
Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet. 2002 Dec. 111(6):477-500. [Medline].
Wang CC, Chang JG, Ferrance J, et al. Quantification of SMN1 and SMN2 genes by capillary electrophoresis for diagnosis of spinal muscular atrophy. Electrophoresis. 2008 Jul. 29(13):2904-11. [Medline].
Umphred DA, ed. Neurological Rehabilitation. 5th ed. St Louis, Mo: Mosby Elsevier; 2007.
Madsen KL, Hansen RS, Preisler N, Thogersen F, Berthelsen MP, Vissing J. Training improves oxidative capacity, but not function, in spinal muscular atrophy type III. Muscle Nerve. 2015 Aug. 52 (2):240-4. [Medline].
Rodillo E, Marini ML, Heckmatt JZ, et al. Scoliosis in spinal muscular atrophy: review of 63 cases. J Child Neurol. 1989 Apr. 4(2):118-23. [Medline].
Yasuma F, Kuru S, Konagaya M. Dilated cardiomyopathy in Kugelberg-Welander disease: coexisting sleep disordered breathing and its treatment with continuous positive airway pressure. Intern Med. 2004 Oct. 43(10):951-4. [Medline]. [Full Text].
Merlini L, Granata C, Bonfiglioli S, et al. Scoliosis in spinal muscular atrophy: natural history and management. Dev Med Child Neurol. 1989 Aug. 31(4):501-8. [Medline].
Swoboda KJ, Kissel JT, Crawford TO, et al. Perspectives on clinical trials in spinal muscular atrophy. J Child Neurol. 2007 Aug. 22(8):957-66. [Medline].
Il'ina NA, Antipova RI, Khokhlov AP. [Use of lithium carbonate to treat Kugelberg--Welander spinal amyotrophy]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1980. 80(11):1657-60. [Medline].
Tzeng AC, Cheng J, Fryczynski H, et al. A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. Am J Phys Med Rehabil. 2000 Sep-Oct. 79(5):435-40. [Medline].
Merlini L, Solari A, Vita G, et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J Child Neurol. 2003 Aug. 18(8):537-41. [Medline].
de Groot IJ, de Witte LP. Physical complaints in ageing persons with spinal muscular atrophy. J Rehabil Med. 2005 Jul. 37(4):258-62. [Medline].
Liveson JA. Peripheral Neurology: Case Studies in Electrodiagnosis. 2nd ed. Philadelphia, Pa: FA Davis; 1991.
Menkes JH. Textbook of Child Neurology. 5th ed. Baltimore, Md: Williams & Wilkins; 1995.
Swaiman KF, Ashwal S, Ferriero DM, eds. Pediatric Neurology: Principles and Practice. 4th ed. Philadelphia, Pa: Mosby; 2006.
Ropper AH, Brown RH. Adams and Victor's Principles of Neurology. 8th ed. New York, NY: McGraw-Hill Medical; 2005.
Younger DS, Gordon PH. Diagnosis in neuromuscular diseases. Neurol Clin. Feb 1 1996. 14:135-68.
Zeinos M, Sampath J, Cole C, et al. Operative treatment for hip subluxations in spinal muscular atrophy. J Bone Joint Surg. 2005. 87-B:1541-4.